Bruce A. Cree MD
Neuroimmunology/Multiple Sclerosis
Clinical Professor, Neurology, UCSF School of Medicine
Join to View Full Profile
1651 4th StSuite 252San Francisco, CA 94158
Phone+1 415-353-2069
Fax+1 415-353-2633
Dr. Cree is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bruce Cree is a San Francisco-based neurologist with subspecialties in neuroimmunology and multiple sclerosis. He completed his medical education at the University of California San Francisco School of Medicine in 1997, followed by an internal medicine internship and a neurology residency. Dr. Cree is actively involved in multiple sclerosis research, with numerous publications in well-regarded journals, and has served as a lead investigator in multiple clinical trials.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
Sutter Health/California Pacific Medical CenterInternship, Internal Medicine, 1997 - 1998
University of California San Francisco School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2001 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Safety and Tolerability of Rituximab in Neuromyelitis Optica Start of enrollment: 2004 Jan 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.Hans-Peter Hartung, Derrick Robertson, Lawrence Steinman, Douglas L Arnold, Peiqing Qian
Neurology and Therapy. 2026-06-01 - Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.Bruce A C Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W Lindsey
Annals of Clinical and Translational Neurology. 2026-05-12 - Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.Krista M McCutcheon, Aaron Bodansky, Thomas T Ngo, Colette Caspar, Sydney Quintana
Neurology(R) Neuroimmunology & Neuroinflammation. 2026-05-01
Lectures
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Pittsburgh, Pennsylvania - 5/4/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Cleveland, Ohio - 4/27/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Denver, Colorado - 4/20/2013
Press Mentions
International Neurology Conference Featured UCSF ExpertsApril 22nd, 2025- Can Central Vein Sign Distinguish Multiple Sclerosis from Its Most Common Mimic?March 20th, 2025
- Smoldering MS May Warrant Unique Diagnosis, Treatment, and Research StrategiesNovember 7th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
